Cost Effectiveness of Ruxolitinib Versus Best Available Therapy For The Treatment of Myelofibrosis From Public Health Perspective In Chile

Nov 1, 2016, 00:00 AM
10.1016/j.jval.2016.09.1404
https://www.valueinhealthjournal.com/article/S1098-3015(16)32770-X/fulltext
Section Title : Disease-Specific Studies
Section Order : 1319
First Page : A590
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)32770-X&doi=10.1016/j.jval.2016.09.1404
HEOR Topics :
Tags :
Regions :